ReviewClinical reviews in allergy & immunology2026
Cytoreduction is a Valid Option for Treatment and Prevention of Anaphylaxis in Systemic Mastocytosis: Case Report and Literature Review.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Systemic mastocytosis (SM) is a myeloproliferative disorder marked by accumulation of clonal mast cells (MC) and a 100-fold increased risk of potentially life-threatening anaphylaxis not fully preventable with antimediator treatments. Omalizumab can be effective but is off-label and variably available. The effect of cytoreductive treatments such as interferon-alpha, cladribine, and tyrosine kinase inhibitors (TKIs) on anaphylaxis in SM remains unclear. We present a patient with indolent systemic mastocytosis and recurrent life-threatening anaphylaxis despite maximum antimediator treatment and omalizumab who experienced immediate resolution of ongoing anaphylaxis upon initiation of midostaurin treatment. No anaphylaxis recurrence was observed during 25 months of follow-up on midostaurin. A literature review on cytoreduction and anaphylaxis retrieved 18 studies. Despite the limited quality of evidence, a clear trend towards reduction of anaphylaxis-like symptoms was seen across all agents and SM subtypes with resolution and/or improvement noted in 95% of cases with a prior history of anaphylaxis. Immediate resolution of ongoing anaphylaxis observed in our case and the literature suggest cytoreduction can be used for treatment of refractory anaphylaxis and prevention of recurrent anaphylaxis in SM. Further exploration of cytoreduction for these indications is warranted.
Indexed as
Identifiers
41721947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.